Coeptis Therapeutics Holdings, Inc. (COEP): Investment Report

Overview

Coeptis Therapeutics Holdings, Inc. is a biopharmaceutical company that has the potential to disrupt conventional treatment paradigms and improve patient outcomes through its cell therapy platforms for cancer, autoimmune, and infectious diseases. As the company continues to advance its product pipeline, this report provides an in-depth analysis of COEP's financial performance, growth prospects, and recent news updates, making it an essential read for investors looking to stay ahead of the curve.

Core Metrics

• Current price: $0.2019 USD
• 52-week high: $1.38 USD
• 52-week low: $0.174 USD
• Market Cap: $7.49 million USD
• P/E Ratio: N/A
• Earnings per Share: -$0.51 USD
• 50-day average: $0.26704 USD
• 200-day average: $0.51877 USD
• Analyst Recommendations: Hold (1 analyst)

Financial Performance

Coeptis Therapeutics Holdings, Inc. reported a net loss of $16.87 million in Q2 2024, with an EBITDA of -$16.87 million. The company's total cash stood at $1.03 million, with a free cash flow of -$9.32 million and an operating cash flow of -$7.46 million. While the company's financial performance may seem challenging, its focus on development and advancement of its product pipeline could potentially lead to significant growth opportunities in the future.

Growth Prospects

Coeptis Therapeutics Holdings, Inc. has a robust product pipeline, including CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, and SNAP-CAR, a CAR T cell therapy platform. The company's co-development agreement with Vici Health Sciences, LLC, to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease, also presents a significant growth opportunity. As the company continues to advance its product pipeline, it is essential to monitor its progress and potential breakthroughs, which could lead to significant growth prospects.

News and Updates

Recently, Coeptis Therapeutics Holdings, Inc. reported its Q2 2024 earnings, with a net loss of $16.87 million. The company's stock price has been volatile, with a 52-week high of $1.38 and a 52-week low of $0.174. In other news, a major MMS scandal rocked COEP Technological University, which is unrelated to Coeptis Therapeutics Holdings, Inc.

Upgrades and Downgrades

In recent months, EF Hutton has reiterated its Buy rating on Coeptis Therapeutics Holdings, Inc. on several occasions, while Ladenburg Thalmann initiated coverage with a Buy rating in September 2023. JonesTrading also initiated coverage with a Buy rating in April 2023. These ratings suggest that analysts believe the company has significant growth potential ahead.

Summary

In summary, Coeptis Therapeutics Holdings, Inc. is a biopharmaceutical company with a robust product pipeline and significant growth opportunities. While the company's financial performance may seem challenging, its focus on development and advancement of its product pipeline could lead to significant breakthroughs and growth prospects. As the company continues to advance its product pipeline, it is essential to monitor its progress and potential breakthroughs, which could lead to significant growth opportunities for investors.

Disclosures

The information on this website should not be construed as or relied upon in any manner as investment, legal, tax, or other advice. You should consult your own advisers as to legal, business, tax, and other related matters concerning any investment. Any projections, estimates, forecasts, targets, prospects and/or opinions expressed in these materials are subject to change without notice and may differ or be contrary to opinions expressed by others. Any charts provided here or on other content distribution outlets are for informational purposes only, and should not be relied upon when making any investment decision. Under no circumstances should any information provided on this website or social media platforms be construed as an offer soliciting the purchase or sale of any security, nor should it be construed as an offer to provide investment advisory services.